ASCO Virtual Meeting Program - MD Anderson Cancer Center

MD Anderson at the 2020 ASCO Annual Meeting

May 29-31, 2020

MD Anderson Cancer Center Presentations at 2020 ASCO Annual Meeting

STREAMING PRESENTATIONS

Saturday, May 30

1:00 ? 2:30 p.m. EDT

Special Clinical Science

Symposium

Harnessing Immunotherapy with Novel

Discussion: Tumor-Specific Vaccines: Lessons Learned from HPV

Approaches Beyond Checkpoint Inhibitors

Michael A. Curran, Ph.D.

1:00 ? 2:30 p.m. EDT

Special Clinical Science Symposium

102: Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced David S. Hong, M.D.

Harnessing Immunotherapy with Novel solid tumors

Approaches Beyond Checkpoint Inhibitors

Sunday, May 31

10:30 a.m. ? 12:00 p.m. EDT

Special Clinical Science Symposium

Drug Development for Rare Mutations: The Opportunity to Unite and Conquer!

109: Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors

Vivek Subbiah M.D.

1:00 ? 3:00 p.m. EDT

Plenary Session

Discussion of LBA4: Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study

Michael J. Overman, M.D.

2

MD Anderson Cancer Center Presentations at 2020 ASCO Annual Meeting

ON-DEMAND CLINCAL SCIENCE SYMPOSIUM PRESENTATIONS

Tumor Intrinsic and Extrinsic Factors Affecting Immunotherapy Response in Head and Neck Cancer

Discussion: Of Bugs and Drugs: How Our Microbiome Saves Us

Ann Klopp, M.D., Ph.D.

ON-DEMAND ORAL PRESENTATIONS

Cancer Prevention, Risk Reduction, and Genetics

Discussion: Seek and Ye Shall Find: Germline Mutations in Somatic Profiling

Funda Meric-Bernstam, M.D.

Developmental Therapeutics-- 3008: Correlation of pathogenic POLE mutations with clinical benefit to

Immunotherapy

immune checkpoint inhibitor therapy.

Benjamin Garmezy, M.D.

Developmental Therapeutics-- Discussion: Using Genomics to Select for Checkpoint Blockade Immunotherapy

Ferdinandos Skoulidis, M.D., Ph.D.

Developmental Therapeutics-- Molecularly Targeted Agents and Tumor Biology

3506: Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.

Senthil Damodaran, M.D. Ph.D.

Gastrointestinal Cancer-- Colorectal and Anal

4001: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).

Scott Kopetz, M.D. Ph.D.

Genitourinary Cancer--Kidney and Bladder

5003: Phase II study of the oral HIF-2 inhibitor MK-6482 for Von HippelLindau disease?associated renal cell carcinoma.

Eric Jonasch, M.D.

Genitourinary Cancer--

5504: Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or

Prostate, Testicular, and Penile without abiraterone (AA) in localized high-risk prostate cancer (LHRPC).

Eleni Efstathiou, M.D. Ph.D.

Hematologic Malignancies-- 7500: Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the

Leukemia, Myelodysplastic

BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic

Syndromes, and Allotransplant malignancies.

Curtis Lachowiez, M.D.

3

MD Anderson Cancer Center Presentations at 2020 ASCO Annual Meeting

Hematologic Malignancies-- 7501: Effect of enasidenib (ENA) plus azacitidine (AZA) on complete

Leukemia, Myelodysplastic

remission and overall response versus AZA monotherapy in mutant-

Syndromes, and Allotransplant IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).

Courtney Dinardo M.D.

Hematologic Malignancies-- 7508: Updated results from phase I dose-escalation study of AMG 330, a

Leukemia, Myelodysplastic

bispecific T-cell engager molecule, in patients with relapsed/refractory

Farhad Ravandi, M.D.

Syndromes, and Allotransplant acute myeloid leukemia (R/R AML).

Hematologic Malignancies-- Lymphoma and Chronic Lymphocytic Leukemia

8002: First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study.

Sattva Neelapu, M.D.

Hematologic Malignancies-- Plasma Cell Dyscrasia

Discussion: Guns N' Roses: CAR T in Multiple Myeloma

Krina K. Patel, M.D.

Lung Cancer--Non-Small Cell Discussion: Limited-Stage Small Cell Lung Cancer: Have We Finally

Local-Regional/Small Cell/Other Thoracic Cancers

Defined Radiation Standards?

Melanoma/Skin Cancers

10008: Single-center phase I/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).

Percy Lee, M.D. Isabella Glitza, M.D. Ph.D.

Melanoma/Skin Cancers

Discussion: Adjuvant and Neoadjuvant Therapies in 2020

Rodabe Amaria, M.D.

Pediatric Oncology I Sarcoma Symptoms and Survivorship

10508: Phase II study of antidisialoganglioside antibody, dinutuximab, in

combination with GM-CSF in patients with recurrent osteosarcoma

Pooja Hingorani, M.D.

(AOST1421): A report from the Children's Oncology Group.

11505: Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma Christina Roland, M.D. (UPS) and dedifferentiated liposarcoma (DDLPS).

12006: Neuroleptic rotation for refractory agitation in cancer patients with

delirium in the acute palliative care unit: A double-blind randomized

David Hui, M.D.

clinical trial.

4

MD Anderson Cancer Center Presentations at 2020 ASCO Annual Meeting

ON-DEMAND POSTER DISCUSSION PRESENTATIONS

Breast Cancer-- Local/Regional/Adjuvant

509: Immune phenotype and response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC).

Clinton Yam, M.D.

Breast Cancer-- Local/Regional/Adjuvant

Breast Cancer--Metastatic

517: Comprehensive profiling of androgen receptor-positive (AR+) triple-

negative breast cancer (TNBC) patients (pts) treated with standard

Bora Lim, M.D.

neoadjuvant therapy (NAT) +/- enzalutamide.

1018: Exploring impact of mutations in non-BRCA DNA damage response

(DDR) and non-DDR genes on efficacy in phase III EMBRACA study of talazoparib (TALA) in patients (pts) with germline BRCA1/2 mutated

Jennifer Litton, M.D.

(gBRCAm) HER2-negative (HER2-) advanced breast cancer (ABC).

Care Delivery and Regulatory Discussion: Using Patient-Reported Outcomes to Inform Clinical Trials

Policy

and Clinical Practice

Ishwaria M. Subbiah, M.D.

Care Delivery and Regulatory Policy

2020 : Absence of optimism bias in industry-sponsored cancer trials.

Sonal Noticewala, M.D.

Central Nervous System Tumors

2511: Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM).

Shiao-Pei Weathers, M.D.

Central Nervous System Tumors

2515: A phase I/II clinical trial of autologous CMV-specific T cells in glioblastoma (GBM) patients to reveal a lack of immune effector function.

Shiao-Pei Weathers, M.D.

Developmental Therapeutics-- 3511: CodeBreak 100: Phase I study of AMG 510, a novel

Molecularly Targeted Agents KRASG12C inhibitor, in patients (pts) with advanced solid tumors other

and Tumor Biology

than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

David S. Hong, M.D.

Genitourinary Cancer--Kidney 5015 : ERDAFITINIB in locally advanced or metastatic urothelial

and Bladder

carcinoma (mUC): Long-term outcomes in BLC2001.

Arlene O. Siefker-Radtke, M.D.

Genitourinary Cancer-- Prostate, Testicular, and Penile

Discussion: Promising Therapeutic Targets in Prostate Cancer

Ana Aparicio, M.D.

5

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download